Transgender Health and PMDD: Hormones, Identity and Evidence-Based Care
Premenstrual dysphoric disorder remains a condition that sits at the edge of medical understanding. When gender identity is brought into the picture, that uncertainty becomes even more apparent. Yet this is not a theoretical issue. Anyone with ovaries can experience PMDD, regardless of how they identify, and that includes transgender men and non-binary individuals. Although organisations such as the International Association for Premenstrual Disorders have begun to acknowledge this, the evidence base remains limited and clinical guidance is still evolving.
PMDD as a neurobiological condition, not an identity-based one
At its core, PMDD is not a condition of identity. It is a condition of neurobiology. The defining feature is an abnormal brain response to the normal hormonal changes that occur after ovulation. Oestrogen and progesterone fluctuate in a predictable way across the menstrual cycle, but in individuals with PMDD, the central nervous system reacts in a way that produces significant mood and cognitive symptoms. This means PMDD is fundamentally linked to ovarian function, not to being female as an identity category. Separating these concepts allows for a clearer, more precise approach to care.
When PMDD and gender dysphoria intersect
For those assigned female at birth who identify as male or non-binary, menstruation itself can be psychologically distressing. When PMDD is present, this distress is not only cyclical but intensified. The luteal phase can bring a combination of low mood, irritability, anxiety and cognitive overwhelm, and these symptoms may be experienced through the lens of gender dysphoria. Rather than simply feeling unwell, some individuals describe a sense of being pulled back into a bodily experience that feels misaligned with their identity. The cyclical nature of PMDD can therefore create a repeated monthly destabilisation, both biologically and psychologically, which is not well captured in traditional frameworks of care.
The role and limitations of hormone-based treatments
Hormonal treatment in this context becomes more complex than in standard PMDD management. There is a growing narrative in parts of women’s health that hormone replacement, particularly progesterone, can resolve PMDD symptoms. The current evidence does not support this as a universal approach. In many individuals, progesterone appears to play a role in triggering symptoms rather than alleviating them. Research suggests that PMDD arises from sensitivity to hormonal change rather than deficiency, meaning that adding hormones does not reliably solve the problem and may in some cases worsen it. For transgender individuals, this issue is further complicated by the fact that hormones are not simply therapeutic tools but are closely tied to identity and gender affirmation.
Treatment approaches prior to or alongside transition
Before or alongside any gender-affirming transition, the principles of PMDD treatment remain broadly the same. The aim is either to suppress ovulation and stabilise hormonal fluctuations, or to reduce the brain’s response to those fluctuations. Suppressing ovulation can remove the cyclical hormonal changes that drive PMDD, and this can be achieved through continuous hormonal contraception or, in more severe cases, through GnRH analogues. For many transgender individuals, reducing or stopping menstruation may also alleviate aspects of gender dysphoria, which means this approach can address both biological and psychological components at the same time.
Selective serotonin reuptake inhibitors remain one of the most evidence-based treatments for PMDD. These medications work by modulating the brain’s response to hormonal changes rather than altering the hormones themselves. They can be used continuously or during the luteal phase and are effective for many individuals, particularly where symptoms include significant anxiety or mood disturbance. Psychological support also has an important role. Although there is no therapy designed specifically for PMDD, approaches such as cognitive behavioural therapy or acceptance and commitment therapy can help individuals understand and manage the cyclical nature of their symptoms. In the context of gender dysphoria, this often involves helping individuals navigate the interaction between physical symptoms and identity in a way that feels coherent and supportive.
The impact of testosterone on PMDD symptoms
Testosterone therapy changes the hormonal environment in a more fundamental way. In transmasculine individuals, testosterone typically suppresses ovulation over time, which reduces or eliminates the cyclical hormonal fluctuations that underpin PMDD. Many individuals therefore experience an improvement in symptoms once testosterone therapy is established. However, this effect is not always immediate. Ovulation may continue intermittently in the early stages of treatment, and some individuals may still notice cyclical symptoms during this period. The lack of robust research in this area means that clinical decisions are often based on physiological reasoning and careful monitoring rather than high-quality trial data.
Surgical options and longer-term considerations
In cases where PMDD is severe and resistant to other treatments, surgical options may be considered. Removal of the ovaries eliminates the hormonal trigger for PMDD entirely, allowing for a stable hormonal state through replacement therapy. For some transgender individuals, this may align with gender-affirming surgical goals. However, this is a significant and irreversible intervention, and it requires careful consideration of long-term implications, including bone health, cardiovascular risk, and the need for ongoing hormone replacement.
Trans women and PMDD-like symptoms
The situation is different for trans women. Without ovaries, there is no ovulation and therefore no classical PMDD. However, some trans women report experiencing cyclical mood symptoms while on hormone therapy. These symptoms can resemble premenstrual changes, although they are not driven by the same biological mechanism. The current evidence in this area is limited and largely anecdotal, and it remains unclear whether these experiences reflect hormone sensitivity, fluctuations in dosing, or broader neurobiological responses to sex hormones.
Working within uncertainty
One of the most important aspects of this topic is recognising how much remains unknown. There are no large-scale studies examining PMDD specifically in transgender populations, and there are no tailored clinical guidelines. Most recommendations are extrapolated from research in cisgender women, which does not always translate cleanly. This creates a degree of uncertainty in clinical practice, but it also highlights the importance of individualised care.
A thoughtful approach to PMDD in transgender individuals moves away from rigid protocols and towards a more integrated understanding. It recognises that PMDD is a biological condition rooted in hormone sensitivity, while also acknowledging that gender identity shapes how that condition is experienced. It accepts that hormonal treatments can both help and harm depending on the individual, and that psychological context is central to how symptoms are perceived and managed. Above all, it requires listening carefully and building a plan that reflects both the biology and the lived experience of the person in front of you.
FAQ
-
Yes, if they have ovaries and are ovulating, because PMDD is linked to ovarian function rather than gender identity.
-
Testosterone often improves symptoms by suppressing ovulation, although this is not always immediate or complete.
-
It is not typically helpful and may worsen symptoms in individuals with hormone sensitivity.
-
They do not experience classical PMDD because they do not ovulate, although some may report similar symptoms related to hormone therapy.
-
Treatment usually involves reducing hormonal fluctuations or modifying the brain’s response to them, using approaches such as ovulation suppression, SSRIs, and psychological support tailored to the individual.